Business
REG - Novacyt S.A. - Notice of Results
REG - Novacyt S.A. - Notice of Results
About this update from Novacyt Sas
RNS Number : 7766Z Novacyt S.A. 18 September 2025 Novacyt S.A.("Novacyt", the "Company" or the "Group")Notice of resultsParis, France, and Manchester, UK - 18 September 2025 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), the international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that it will report its unaudited interim results for the six months ended 30 June 2025 on Tuesday 30 September 2025.ContactsNovacyt SAhttps://novacyt.com/investorsLyn Rees, Chief Executive Officer Via Walbrook PRSteve Gibson, Chief Financial Officer SP Angel Corporate Finance LLP (Nominated Adviser and Broker)+44 (0)20 3470 0470Matthew Johnson / Charlie Bouverat (Corporate Finance)Vadim Alexandre / Rob Rees (Corporate Broking)Singer Capital Markets (Joint Broker)+44 (0) 20 7496 3000Tom Salvesen / Phil Davies / James Fischer / Samed EthemiAllegra Finance (French Listing Sponsor)Rémi Durgetto / Yannick Petit +33 (1) 42 22 10 10 [email protected] / [email protected] PR (Financial PR & IR)Paul McManus / Lianne ApplegarthAlice Woodings+44 (0)20 7933 8780 or [email protected]+44 (0)7980 541 893 / +44 (0)7584 391 303 +44 (0)7407 804 654About Novacyt Group (www.novacyt.com)Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.The Company is divided into three business segments:ClinicalBroad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests· Precision Medicine: DPYD genotyping assay· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panelInstrumentationPortfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:· Ranger® Technology: automated DNA sample preparation and target enrichment technology· genesig q16 and q32 real-time quantitative PCR (qPCR) instrumentsResearch Use Only ...